Key result
Dedicated transfemoral TAVI achieves 100% technical success in severe AR after prior cardiac surgery.
Why the study?
Transcatheter aortic valve implantation is emerging as a promising therapy for severe aortic regurgitation in high-risk patients, but data on dedicated devices in patients with prior cardiac surgery are limited.
Does transfemoral TAVI using a dedicated transcatheter heart valve achieve technical success and safety in patients with severe aortic regurgitation and prior cardiac surgery at prohibitive surgical risk?
Observational (n=10)
No
Does transfemoral TAVI using a dedicated transcatheter heart valve achieve technical success and safety in patients with severe aortic regurgitation and prior cardiac surgery at prohibitive surgical risk?
Transfemoral TAVI using a dedicated device is technically feasible and safe for patients with severe noncalcified aortic regurgitation and prior cardiac surgery who are at prohibitive surgical risk.
Answers are grounded in this paper and cite their sources.
May support use in prohibitive-risk AR with prior surgery; leaves open confirmation in prospective trials before practice change.
All articles of this category (opens in new window) Background: Transcatheter aortic valve implantation (TAVI) is emerging as a promising interventional therapy for severe aortic regurgitation (AR) in selected high-risk patients. This study evaluated the performance of a dedicated transcatheter heart valve (THV) in patients receiving TAVI for native pure noncalcified AR at prohibitive risk for reoperation. Methods: This single-center observational study included 10 consecutive patients with severe AR and prior cardiac surgery who underwent transfemoral TAVI using the JenaValve Trilogy system (JenaValve Technology, Irvine, CA). All cases were deemed at prohibitive surgical risk by the local heart team. Results: Median age was 67 years (IQR, 62–73), and 60% were male. The annular perimeter was 79.7 mm (IQR, 74.5–82.1), the mean transvalvular pressure gradient was 7.5 mmHg (IQR, 6.2–9.5), and the left ventricular ejection fraction was 54.0% (IQR, 50.5–55.0). Valve sizes used were 23/25/27 mm in 5/1/4 patients (50/10/40%). Conscious sedation or local anesthesia was applied in 50% of procedures. Median procedure time was 88.5 minutes (IQR, 78.0–110.0), and median contrast volume was 210 mL (IQR, 160.0–280.0). Technical success was achieved in all cases according to VARC-3 criteria, with no conversions to surgery. Median length of stay was 5 days (IQR, 4–13). At discharge, one echocardiogram was not available. Paravalvular leakage was none or trace in eight patients (89%) and mild in one patient (11%); the mean transvalvular pressure gradient was 4.0 mmHg (IQR, 3.5–6.0). After exclusion of the four patients with prior pacemaker implantation, one of six patients (17%) required a new permanent pacemaker. No patient had a stroke, and one patient had a minor vascular access complication. Mortality at 30 days was 0%. One patient and prior left ventricular assist device implantation, died 53 days after the procedure. Conclusion: In this single-center experience, the use of a dedicated THV for TAVI in patients with AR and after prior cardiac surgery demonstrated high technical success rates and favorable in-hospital outcomes, supporting its role as a promising therapeutic option for severe AR in prohibitive surgical risk patients. Publication History Article published online: 17 February 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
No takes yet. Share an insight, caveat, or question.
Wienemann et al. (2026) conducted an observational in Severe aortic regurgitation with prior cardiac surgery (n=10). Transfemoral TAVI (JenaValve Trilogy system) was evaluated on Technical success according to VARC-3 criteria. Transfemoral TAVI using a dedicated transcatheter heart valve achieved 100% technical success and 0% 30-day mortality in patients with severe aortic regurgitation and prior cardiac surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: